Literature DB >> 30323045

Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa.

Laurent Poirel1,2,3, José-Manuel Ortiz De La Rosa4,2, Nicolas Kieffer4,3, Véronique Dubois5,6, Aurélie Jayol4,2,3,7, Patrice Nordmann4,2,3,8.   

Abstract

A clinical Pseudomonas aeruginosa isolate resistant to all β-lactams, including ceftolozane-tazobactam and carbapenems, was recovered. It belonged to sequence type 235 and produced the extended-spectrum β-lactamase (ESBL) GES-6 differing from GES-1 by two amino acid substitutions (E104K and G170S). GES-6 possessed an increased hydrolytic activity toward carbapenems and to ceftolozane and a decreased susceptibility to β-lactamase inhibitors compared to GES-1, except for avibactam. We show here that resistance to ceftolozane-tazobactam may occur through acquisition of a specific ESBL in P. aeruginosa but that ceftazidime-avibactam combination remains an effective alternative.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  ESBL; GES-6; Pseudomonas aeruginosa; ceftolozane-tazobactam

Mesh：

Substances：

Year:  2018        PMID： 30323045      PMCID： PMC6325188          DOI： 10.1128/AAC.01809-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  32 in total

1.  Rapid detection of carbapenemase-producing Pseudomonas spp.

Authors:  Laurent Dortet; Laurent Poirel; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

2.  Carbapenem resistance mediated by blaOXA-181 in Pseudomonas aeruginosa.

Authors:  Danièle Meunier; Michel Doumith; Jacqueline Findlay; Nazim Mustafa; Kim Mallard; James Anson; Stavroula Panagea; Rachel Pike; Laura Wright; Neil Woodford; Katie L Hopkins
Journal:  J Antimicrob Chemother       Date:  2016-03-23       Impact factor: 5.790

3.  In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa.

Authors:  Pablo A Fraile-Ribot; Xavier Mulet; Gabriel Cabot; Ester Del Barrio-Tofiño; Carlos Juan; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 4.  Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis.

Authors:  Annabelle C Lee; Andrew L Jones
Journal:  Paediatr Respir Rev       Date:  2018-05-18       Impact factor: 2.726

5.  GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem.

Authors:  L Poirel; G F Weldhagen; T Naas; C De Champs; M G Dove; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Factors affecting the isolation of CCC DNA from Streptomyces lividans and Escherichia coli.

Authors:  T Kieser
Journal:  Plasmid       Date:  1984-07       Impact factor: 3.466

7.  Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.

Authors:  Krisztina M Papp-Wallace; Christopher R Bethel; Anne M Distler; Courtney Kasuboski; Magdalena Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

8.  A kinetic analysis of the inhibition of FOX-4 β-lactamase, a plasmid-mediated AmpC cephalosporinase, by monocyclic β-lactams and carbapenems.

Authors:  Krisztina M Papp-Wallace; Susana Mallo; Christopher R Bethel; Magdalena A Taracila; Andrea M Hujer; Ana Fernández; Julian A Gatta; Kerri M Smith; Yan Xu; Malcolm G P Page; Eric Desarbre; Germán Bou; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2013-11-13       Impact factor: 5.790

9.  Novel GES/IBC extended-spectrum beta-lactamase variants with carbapenemase activity in clinical enterobacteria.

Authors:  Sofia Vourli; Panagiota Giakkoupi; Vivi Miriagou; Eva Tzelepi; Alkiviadis C Vatopoulos; Leonidas S Tzouvelekis
Journal:  FEMS Microbiol Lett       Date:  2004-05-15       Impact factor: 2.742

10.  Unravelling the genome of a Pseudomonas aeruginosa isolate belonging to the high-risk clone ST235 reveals an integrative conjugative element housing a blaGES-6 carbapenemase.

Authors:  João Botelho; Filipa Grosso; Luísa Peixe
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790
View more
  12 in total

Review 1.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

2.  A 2.5-years within-patient evolution of a Pseudomonas aeruginosa with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment.

Authors:  Thibaud Boulant; Agnès B Jousset; Rémy A Bonnin; Aurélie Barrail-Tran; Adrien Borgel; Saoussen Oueslati; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-10-21       Impact factor: 5.191

3.  NDM-35-Producing ST167 Escherichia coli Highly Resistant to β-Lactams Including Cefiderocol.

Authors:  Laurent Poirel; José Manuel Ortiz de la Rosa; Zeynep Sakaoglu; Ayda Kusaksizoglu; Mustafa Sadek; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2022-07-11       Impact factor: 5.938

Review 4.  Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics.

Authors:  Shugang Qin; Wen Xiao; Chuanmin Zhou; Qinqin Pu; Xin Deng; Lefu Lan; Haihua Liang; Xiangrong Song; Min Wu
Journal:  Signal Transduct Target Ther       Date:  2022-06-25

5.  Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant β-Lactamases and Their Increasing Importance.

Authors:  Andrea M Hujer; Christopher R Bethel; Magdalena A Taracila; Steven H Marshall; Laura J Rojas; Marisa L Winkler; Ronald E Painter; T Nicholas Domitrovic; Richard R Watkins; Ayman M Abdelhamed; Roshan D'Souza; Andrew R Mack; Richard C White; Thomas Clarke; Derrick E Fouts; Michael R Jacobs; Katherine Young; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2022-04-18       Impact factor: 5.938

6.  Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.

Authors:  Mustafa Sadek; Mario Juhas; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

7.  Evaluation of the Xpert Carba-R NxG Assay for Detection of Carbapenemase Genes in a Global Challenge Set of Pseudomonas aeruginosa Isolates.

Authors:  Christian M Gill; Tomefa E Asempa; Isabella A Tickler; Caitlin Dela Cruz; Fred C Tenover; David P Nicolau
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

Review 8.  Emerging therapies against infections with Pseudomonas aeruginosa.

Authors:  Burkhard Tümmler
Journal:  F1000Res       Date:  2019-08-07

9.  Extensively Drug-Resistant Pseudomonas aeruginosa ST309 Harboring Tandem Guiana Extended Spectrum β-Lactamase Enzymes: A Newly Emerging Threat in the United States.

Authors:  Ayesha Khan; Truc T Tran; Rafael Rios; Blake Hanson; William C Shropshire; Zhizeng Sun; Lorena Diaz; An Q Dinh; Audrey Wanger; Luis Ostrosky-Zeichner; Timothy Palzkill; Cesar A Arias; William R Miller
Journal:  Open Forum Infect Dis       Date:  2019-06-06       Impact factor: 3.835

10.  Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.

Authors:  Catherine L Tooke; Philip Hinchliffe; Pauline A Lang; Adrian J Mulholland; Jürgen Brem; Christopher J Schofield; James Spencer
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.938
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.